Top news of the week: 10.02.2023.
How Purdue's $272M addiction payout funded a new home for its discarded non-opioid research
Don Kyle spent more than 20 years working for Purdue Pharma, right through the US opioid epidemic that led to the company’s rise and eventual infamy. But contrary to Purdue’s focus on ...
Slingshot Biosciences Announces $11 Million in Series A3 Financing
Developing synthetic cells for a range of applications in diagnostics and therapeuticsEMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, a biotechnology company building the ...
Evotec and Related Sciences expand integrated drug discovery and development partnership
EQS-News: Evotec SE / Key word(s): MiscellaneousEvotec and Related Sciences expand integrated drug discovery and development partnership 09.02.2023 / 07:30 CET/CESTThe issuer is solely ...
HCB Joins NPG Health to Create Next Generation Healthcare Offering
Firm Rebrands as Boundless Life Sciences GroupAUSTIN, Texas--(BUSINESS WIRE)--HCB Health announced today it has joined The Next Practices Group (NPG) to become one of the foundational ...
IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics
Structure Therapeutics has completed a $161 million initial public offering (IPO)—by far the largest IPO to date this year.
China-U.S. biotech ventures are where collaboration meets competition
At the 2023 BIO CEO & Investor Conference, experts discussed the role of U.S.-China biotech ventures in delivering for patients worldwide.
Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...
Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform
Prokarium’s mission is to re-engineer evolution into a synthetic biology platform for novel immunotherapiesProceeds will support clinical development of the Company’s lead oncology ...